Rakovina Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Rakovina Therapeutics has a total shareholder equity of CA$3.8M and total debt of CA$1.4M, which brings its debt-to-equity ratio to 36.1%. Its total assets and total liabilities are CA$6.2M and CA$2.4M respectively.
Key information
36.1%
Debt to equity ratio
CA$1.37m
Debt
| Interest coverage ratio | n/a |
| Cash | CA$1.39m |
| Equity | CA$3.81m |
| Total liabilities | CA$2.42m |
| Total assets | CA$6.23m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RKV's short term assets (CA$2.0M) exceed its short term liabilities (CA$1.0M).
Long Term Liabilities: RKV's short term assets (CA$2.0M) exceed its long term liabilities (CA$1.4M).
Debt to Equity History and Analysis
Debt Level: RKV has more cash than its total debt.
Reducing Debt: Insufficient data to determine if RKV's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RKV has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: RKV is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.